Key clinical point: Presence of ctDNA and CTCs was associated with worse triple-negative breast cancer prognosis.

Major finding: 2-year overall survival was 51% for ctDNA- and CTC-positive patients, compared with 76% for patients negative for both markers (hazard ratio, 8.60; P = .0074).

Study details: Prospective analysis of 142 patients with residual TNBC after neoadjuvant therapy.

Disclosures: The study was funded by the Vera Bradley Foundation for Breast Cancer and the Indiana University Grand Challenge Precision Health Initiative. Dr. Radovich and Dr. Schneider reported no relevant disclosures. Dr. Kaklamani disclosed speakers bureau activities and consulting for multiple companies, as well as research funding from Eiasi.